Marco Meglio

GLP-1 medications are revolutionizing treatment for neurological conditions.

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.

Almost 4 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The combination agent breaks ground as the first treatment approved for this indication.

Patients included in the high-dose group demonstrated statistically significant improvements compared to placebo for MDS-UPDRS total score.

The investigators generated a list of 250 genes that are known to regulate individual reactions within the component pathways of the Alzheimer Disease Aberrant Metabolism (ADAM) network.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning.

The FDA will consider the approval of the biologics license application next month.

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

Genetically-indexed inhibition of TNF-TNFR1 signaling was predicted to reduce the risk of Crohn’s disease and ulcerative colitis, and increased the risk of multiple sclerosis.

The study finds that individuals with mothers who had pregestational diabetes had a 2.3-fold increased risk of MS compared to those with non-diabetic mothers.

Fewer patients who received masitinib 4.5 mg/kg/day reached severe dementia stage.

Investigators find frailty is a key risk factor for age-related cognitive dysfunction and dementia.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

The therapy was previously approved to reduce the risk of cardiovascular death, MI, and stroke in patients with ACS or previous MI.

Patients diagnosed with neurologic disorders post-admission were less likely to be discharged home than those with events prior to, or at the time of admission.

ELP Pharma readying plans to continue to study the drug in a phase 3 trial.

Sumifilam could be the first Alzheimer treatment to improve several biomarkers.

As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.